BNP Paribas Financial Markets Increases Position in Charles River Laboratories International, Inc. $CRL

BNP Paribas Financial Markets grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 48.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 162,740 shares of the medical research company’s stock after acquiring an additional 52,861 shares during the quarter. BNP Paribas Financial Markets’ holdings in Charles River Laboratories International were worth $32,463,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Principal Financial Group Inc. increased its stake in shares of Charles River Laboratories International by 84.5% during the third quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock worth $16,384,000 after acquiring an additional 47,954 shares during the period. Madison Asset Management LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth about $1,935,000. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 14.5% during the third quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock worth $49,626,000 after acquiring an additional 40,073 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth about $533,000. Finally, Gotham Asset Management LLC increased its stake in shares of Charles River Laboratories International by 17.3% during the third quarter. Gotham Asset Management LLC now owns 315,755 shares of the medical research company’s stock worth $49,403,000 after acquiring an additional 46,594 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. UBS Group boosted their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Evercore reiterated an “outperform” rating and set a $220.00 price target on shares of Charles River Laboratories International in a research note on Friday, May 8th. Barclays boosted their price target on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 29th. Finally, CLSA upgraded shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and boosted their price target for the stock from $167.00 to $219.00 in a research note on Friday, May 29th. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $208.50.

Charles River Laboratories International Stock Up 3.2%

CRL stock opened at $185.65 on Friday. The company has a market cap of $8.94 billion, a P/E ratio of -49.37, a P/E/G ratio of 2.06 and a beta of 1.46. Charles River Laboratories International, Inc. has a 52 week low of $140.78 and a 52 week high of $228.88. The company’s 50-day moving average price is $171.05 and its 200 day moving average price is $181.57. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.